抗体依赖性细胞介导的细胞毒性
CD38
达拉图穆马
癌症研究
生物
免疫学
单克隆抗体
抗体
细胞生物学
干细胞
川地34
作者
Meisam Naeimi Kararoudi,Yuya Nagai,Ezgi Elmas,Marcelo de Souza Fernandes Pereira,Syed Abbas Ali,Philip Hollingsworth Imus,Darren Wethington,Ivan Borrello,Dean Anthony Lee,Gabriel Ghiaur
出处
期刊:Blood
[Elsevier BV]
日期:2020-06-30
卷期号:136 (21): 2416-2427
被引量:137
标识
DOI:10.1182/blood.2020006200
摘要
Multiple myeloma (MM) is a plasma cell neoplasm that commonly expresses CD38. Daratumumab (DARA), a human monoclonal antibody targeting CD38, has significantly improved the outcome of patients with relapsed or refractory MM, but the response is transient in most cases. Putative mechanisms of suboptimal efficacy of DARA include downregulation of CD38 expression and overexpression of complement inhibitory proteins on MM target cells as well as DARA-induced depletion of CD38high natural killer (NK) cells resulting in crippled antibody-dependent cellular cytotoxicity (ADCC). Here, we tested whether maintaining NK cell function during DARA therapy could maximize DARA-mediated ADCC against MM cells and deepen the response. We used the CRISPR/Cas9 system to delete CD38 (CD38KO) in ex vivo expanded peripheral blood NK cells. These CD38KO NK cells were completely resistant to DARA-induced fratricide, showed superior persistence in immune-deficient mice pretreated with DARA, and enhanced ADCC activity against CD38-expressing MM cell lines and primary MM cells. In addition, transcriptomic and cellular metabolic analysis demonstrated that CD38KO NK cells have unique metabolic reprogramming with higher mitochondrial respiratory capacity. Finally, we evaluated the impact of exposure to all-trans retinoic acid (ATRA) on wild-type NK and CD38KO NK cell function and highlighted potential benefits and drawbacks of combining ATRA with DARA in patients with MM. Taken together, these findings provide proof of concept that adoptive immunotherapy using ex vivo expanded CD38KO NK cells has the potential to boost DARA activity in MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI